CVRx (CVRX) has opened Q1 2026 with revenue of US$14.8 million and a reported loss of US$13.1 million, translating to basic EPS of US$0.50, with a share price sitting around US$5.27. The company has seen quarterly revenue range between US$12.3 million and US$16.0 million over the past five reported periods, while basic EPS has stayed in a tight band between US$0.43 and US$0.57 in losses. This keeps the focus firmly on how quickly margins can move toward breakeven. For investors, this set of results keeps the spotlight on whether revenue growth can eventually outpace operating costs and ease the pressure on persistent losses.

See our full analysis for CVRx.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the most common narratives around CVRx's growth potential and ongoing risks.

Losses of US$52.7 million over last year keep profitability out of reach

• On a trailing twelve month basis to Q1 2026, CVRx recorded total revenue of US$59.1 million and a net loss of US$52.7 million, with basic EPS at a loss of US$2.01, showing that most of each revenue dollar is still being absorbed by costs.
• Consensus narrative expects reimbursement improvements and a larger addressable heart failure market to eventually support better margins, but the data here highlights that:
  • Losses have increased at about 11.3% per year over the past five years, and the company is forecast to remain unprofitable for at least the next three years, which challenges the idea of a rapid earnings inflection.
  • Despite these ongoing losses, analysts still model revenue growth of about 21.1% per year over the next three years, so the key tension is whether that growth can materially change the current pattern of heavy net losses.

Revenue growth forecasts of about 16.2% sit beside a 2.4x P/S

• Revenue is forecast to grow at about 16.2% per year while the stock trades on a P/S of 2.4x, compared with 2.7x for the wider US Medical Equipment industry and 5.2x for peers, which frames CVRx as cheaper on sales than many comparables.
• Bullish investors argue this combination of growth and lower P/S could be attractive, yet the current numbers cut both ways:
  • On the positive side, trailing twelve month revenue of US$59.1 million sits alongside those growth forecasts, so the bullish case that top line momentum is real is at least consistent with the reported revenue base.
  • At the same time, the net loss of US$52.7 million over the same period and the expectation that the company will remain unprofitable for three years mean the lower P/S multiple can also be read as the market accounting for persistent losses rather than overlooking them.

Bulls point to this mix of revenue growth and relative value as the core of their thesis, while critics focus on the heavy losses and ask how long shareholders will be willing to wait for the story to change. 🐂 CVRx Bull Case

Recent insider selling and share volatility test the bearish concerns

• Alongside a share price around US$5.27, the stock has shown volatile trading over the past three months, and there has been significant insider selling in that same window, which some investors treat as a caution signal when a company is still loss making.
• Bears argue that this mix of volatility, insider selling, and ongoing losses points to fragile sentiment, but the available figures give a more nuanced picture:
  • On one hand, the trailing twelve month loss of US$52.7 million and forecasts for continued unprofitability line up with the cautious view that the business model has more to prove before the stock can sustain a higher valuation.
  • On the other hand, analysts still see revenue growing at about 16.2% per year and highlight improving reimbursement and an expanding sales footprint, which suggests the business is not standing still even as near term profitability remains pressured.

For a cautious investor, this section of the story is about weighing those execution and governance concerns against the growth data before deciding whether the current price fairly reflects the risk profile. 🐻 CVRx Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for CVRx on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Does this mix of promise and concern match how you see CVRx, or does it feel off? To stress test your view against both sides of the story, take a closer look at the company's 2 key rewards and 3 important warning signs

Explore Alternatives

CVRx combines heavy losses of US$52.7 million, ongoing unprofitability forecasts, and insider selling, which raises real questions about risk and balance sheet resilience.

If this risk profile makes you uneasy, compare it with companies that screen better on stability by checking out the 69 resilient stocks with low risk scores right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.